You have 0 items in your cart
When reading about peptides, medicines and drug development, you’ll frequently encounter the word:
bioavailability.
A research paper might report that a compound has:
“low oral bioavailability”
or researchers may describe a new formulation designed to:
“improve bioavailability.”
But what does that actually mean?
Is 100% bioavailability better?
Why can swallowing a peptide produce very different exposure from other routes studied in research?
And why is oral delivery particularly challenging for many peptides?
Bioavailability is one of the fundamental concepts of pharmacokinetics — and understanding it makes a huge amount of peptide research easier to interpret.
What does bioavailability mean?
Bioavailability describes the rate and extent to which an active compound becomes available in the body at its site of action or in a biological medium used to reflect that availability.
In simpler terms:
How much of the compound actually becomes available — and how quickly?
This is important because the amount of a substance initially introduced into a biological system isn’t necessarily the same as the amount that ultimately becomes available systemically or at its intended target.
What does 50% bioavailability mean?
In a simplified example, imagine researchers administer 100 mg of a compound orally.
If the compound has an absolute bioavailability of 50%, systemic exposure would correspond to roughly half of that administered amount reaching systemic circulation unchanged.
That doesn’t mean the remaining 50% simply vanished in one place.
Several processes may contribute to reduced bioavailability.
The compound might:
not be completely absorbed;
be degraded before absorption;
be metabolised in the intestinal wall;
or
undergo metabolism in the liver before reaching wider circulation.
What does 100% bioavailability mean?
When a compound is administered directly into the bloodstream intravenously, its systemic bioavailability is conventionally treated as 100%.
There isn’t an absorption barrier between the administered compound and systemic circulation.
Researchers can therefore compare exposure following another route with intravenous exposure to estimate absolute bioavailability.
This doesn’t mean intravenous administration makes every compound more effective.
It simply provides an important pharmacokinetic reference.
Is bioavailability the same as absorption?
Not quite.
These terms are closely related but shouldn’t automatically be treated as identical.
Absorption broadly concerns movement of a compound from its site of administration into the body.
Bioavailability considers how much active compound ultimately becomes available systemically or at the relevant site of action, as well as the rate at which this occurs.
A compound could therefore be absorbed from the gastrointestinal tract but undergo substantial metabolism before reaching systemic circulation.
What is oral bioavailability?
Oral bioavailability describes bioavailability following oral administration.
For a conventional oral medicine, several things need to happen successfully.
The compound must survive the gastrointestinal environment.
It must dissolve appropriately.
It must cross biological barriers in the gastrointestinal tract.
It may then pass through the intestinal wall and liver.
Only after navigating these processes does an appropriate amount reach systemic circulation.
This is one reason creating an effective tablet can be considerably more complicated than simply putting an active molecule into a capsule.
Why do many peptides have poor oral bioavailability?
Peptides present particular challenges.
They’re made from amino acids connected by peptide bonds.
The digestive system is specifically designed to break down proteins and peptides.
That means orally introduced peptides can encounter:
stomach acid;
digestive enzymes;
intestinal enzymes;
and a substantial biological barrier formed by the intestinal lining.
Even if a peptide survives degradation, its molecular characteristics may make crossing that barrier difficult.
As a result, many conventional peptides have very low oral bioavailability.
Why does the digestive system break peptides down?
Proteins in food need to be broken into smaller components that the body can process.
The gastrointestinal system therefore contains enzymes capable of breaking peptide bonds.
These include various proteases and peptidases.
That’s useful for digestion.
But it’s a major challenge for researchers trying to deliver an intact therapeutic peptide through the gastrointestinal tract.
The peptide has to survive an environment specifically designed to dismantle molecules like it.
Can peptides be absorbed through the intestine?
Some can, but the process can be difficult and inefficient.
The intestinal wall is designed to regulate what enters circulation.
Small molecules with suitable physicochemical properties may cross relatively easily.
Larger peptide molecules frequently don’t.
Researchers therefore investigate methods of improving:
stability;
permeability;
absorption;
and overall bioavailability.
Why aren’t all peptide medicines tablets?
This is one of the most obvious consequences of peptide bioavailability.
People are accustomed to conventional medicines being available as tablets.
But a molecule that works perfectly when it reaches its biological target might be unsuitable for conventional oral delivery if almost none survives the journey through the gastrointestinal system.
That’s why drug developers may investigate alternative formulations or delivery technologies.
Can scientists improve oral peptide bioavailability?
Yes, and this is an extremely active area of pharmaceutical research.
Approaches can include:
chemical modification of the peptide;
protective formulations;
absorption-enhancing technologies;
enzyme-inhibiting strategies;
and alternative delivery systems.
The challenge is improving exposure while maintaining acceptable safety, stability and reproducibility.
How can semaglutide be available as an oral tablet?
Semaglutide provides a particularly interesting example.
Semaglutide is a peptide-based GLP-1 receptor agonist, yet an oral formulation has been developed.
This required a specialised formulation approach rather than simply turning injectable semaglutide into an ordinary tablet.
The oral formulation uses an absorption-enhancing excipient to help facilitate uptake.
Even then, oral bioavailability remains relatively low.
The important point is that:
Low bioavailability doesn’t necessarily mean zero bioavailability.
If exposure is sufficiently predictable and biologically relevant, a medicine may still be developed successfully.
What is an absorption enhancer?
An absorption enhancer is a substance or technology intended to increase the movement of another compound across a biological barrier.
In oral peptide development, researchers may investigate whether an enhancer can help protect a peptide or increase its ability to cross gastrointestinal barriers.
This is a sophisticated area of formulation science.
It also demonstrates why the formulation of a compound can be almost as important as the active molecule itself.
What is first-pass metabolism?
Another important concept is:
first-pass metabolism.
After a compound is absorbed from the gastrointestinal tract, it commonly travels through the portal circulation to the liver before reaching wider systemic circulation.
During this journey, enzymes in the intestinal wall and liver may metabolise some of the compound.
This can reduce the amount of unchanged active compound reaching systemic circulation.
This process is often called the first-pass effect.
Does first-pass metabolism affect bioavailability?
Yes.
A compound may be absorbed effectively from the intestine but still have relatively low systemic bioavailability if a large proportion is metabolised before reaching wider circulation.
So poor oral bioavailability isn’t always simply an absorption problem.
Metabolism can be equally important.
Bioavailability vs half-life — what’s the difference?
These are both pharmacokinetic concepts, but they answer different questions.
Bioavailability
How much of the active compound becomes available, and at what rate?
Half-life
How quickly does the amount or concentration decline once the compound is present in the body?
A compound could theoretically have:
low bioavailability but a long half-life
or:
high bioavailability but a short half-life.
They’re separate characteristics.
Bioavailability vs potency — what’s the difference?
These are also frequently confused.
Bioavailability concerns exposure to the compound.
Potency relates to how much of a compound is required to produce a particular biological effect.
A highly potent compound can still have poor oral bioavailability.
Likewise, high bioavailability doesn’t automatically mean a compound is particularly potent.
Does higher bioavailability mean better?
Not necessarily.
It’s tempting to think:
100% = excellent
and
10% = poor.
But pharmacology isn’t a percentage competition.
What matters is whether exposure is:
sufficient;
predictable;
reproducible;
and appropriate for the intended research or therapeutic objective.
Increasing exposure isn’t automatically desirable if it also increases unwanted effects.
What is absolute bioavailability?
Absolute bioavailability compares exposure from a particular route with exposure following intravenous administration.
Because intravenous administration provides direct systemic exposure, it’s used as the reference.
Researchers can compare the concentration-time profiles produced by the two routes to estimate how much of the compound becomes systemically available.
What is relative bioavailability?
Relative bioavailability compares two formulations or products rather than necessarily comparing one with intravenous administration.
For example, researchers might compare:
Formulation A
with
Formulation B
containing the same active compound.
This can help determine whether formulation changes alter systemic exposure.
What is bioequivalence?
Bioequivalence is related but different.
Researchers can compare two drug products to determine whether their rate and extent of exposure fall within predefined acceptable limits.
This concept is particularly important in the development and regulation of generic medicines.
Two products containing the same active ingredient aren’t assessed merely by checking whether the label lists the same number of milligrams.
Researchers may need to establish that their pharmacokinetic performance is sufficiently comparable.
How do researchers measure bioavailability?
Researchers commonly measure concentrations of a compound in blood or plasma over time.
This produces a:
concentration-time curve.
Several measurements can then be calculated.
Two you’ll often see are:
AUC
and
Cmax.
What does AUC mean?
AUC stands for:
Area Under the Curve.
Imagine a graph showing:
time along the bottom
and
concentration in plasma up the side.
The area underneath the resulting concentration-time curve provides information about the body’s overall systemic exposure to the compound.
A larger AUC generally indicates greater total exposure under the conditions studied.
What does Cmax mean?
Cmax is the maximum observed concentration.
In simple terms:
How high did the measured concentration peak?
Researchers may also report:
Tmax
which describes the time at which that maximum concentration was reached.
Together, measurements such as AUC, Cmax and Tmax help researchers understand how a compound behaves after administration.
Why can food affect bioavailability?
Food can sometimes alter drug absorption and exposure.
Depending on the compound and formulation, eating may change:
gastric emptying;
intestinal conditions;
dissolution;
absorption;
or other processes affecting pharmacokinetics.
The effect can vary enormously between compounds.
That’s why researchers may conduct dedicated food-effect studies during drug development.
Why does formulation matter?
Two formulations containing the same active molecule can potentially behave differently.
Factors such as:
tablet composition;
particle size;
coatings;
excipients;
release mechanisms;
and delivery technologies
can affect how the active compound becomes available.
This is another reason why simply knowing the name of an active ingredient doesn’t tell you everything about its pharmacokinetics.
What is an excipient?
An excipient is a component of a pharmaceutical formulation other than the principal active ingredient.
Excipients can serve many purposes.
They may help with:
stability;
manufacturing;
dissolution;
delivery;
tablet structure;
or absorption.
They’re therefore not necessarily biologically irrelevant ingredients.
In advanced peptide formulations, excipients can play particularly important roles.
Why does bioavailability matter in peptide research?
Imagine researchers discover a peptide with an extremely interesting effect in cultured cells.
That tells them something about the molecule’s biological potential.
But eventually they need to answer another question:
Can enough intact peptide actually reach its biological target?
A compound might show excellent receptor activity in vitro while having extremely poor exposure in vivo.
That’s where pharmacokinetics becomes critical.
Researchers need to understand:
absorption
bioavailability
distribution
metabolism
half-life
and
clearance.
Interesting receptor activity alone isn’t enough.
Why does this connect to in-vitro vs in-vivo research?
An in-vitro experiment may expose cells directly to a known concentration of a peptide.
The cells don’t necessarily have to deal with:
digestion;
intestinal absorption;
first-pass metabolism;
whole-body distribution;
or systemic clearance.
Inside a living organism, all of those processes can matter.
That’s one reason an impressive laboratory finding doesn’t automatically translate into an equivalent effect in vivo.
Does poor bioavailability mean a peptide doesn’t work?
No.
It means researchers need to understand how much of the compound becomes available under the conditions being studied.
Poor oral bioavailability, for example, doesn’t tell you that the molecule has no biological activity.
It tells you that oral delivery presents a pharmacokinetic challenge.
Those are very different statements.
Why is oral peptide research such a big area?
Tablets offer obvious practical advantages over many other delivery systems.
Successfully delivering complex peptide molecules orally, however, requires researchers to overcome substantial biological barriers.
This has driven research into:
new formulations;
absorption enhancers;
protective technologies;
novel molecular designs;
and even entirely different non-peptide molecules capable of activating peptide-related receptors.
It’s one of the reasons modern metabolic research is increasingly exploring both peptide and non-peptide approaches.
A simple bioavailability glossary
Bioavailability: The rate and extent to which an active compound becomes available.
Absorption: Movement of a compound from its administration site into the body.
First-pass metabolism: Metabolism occurring before an orally absorbed compound reaches wider systemic circulation.
AUC: Area under the concentration-time curve; a measure related to overall exposure.
Cmax: Maximum measured concentration.
Tmax: Time at which maximum concentration is reached.
Absolute bioavailability: Comparison with intravenous exposure.
Relative bioavailability: Comparison between formulations or products.
Bioequivalence: Assessment of whether two products provide sufficiently comparable exposure.
Pharmacokinetics: The study of how compounds move through the body.
The bigger picture
Bioavailability answers a deceptively simple question:
How much of the compound actually becomes available?
For peptide researchers, that question can be crucial.
Discovering a molecule that interacts with an interesting receptor is one challenge.
Delivering enough intact molecule to the relevant biological system can be another challenge entirely.
That’s why modern peptide development doesn’t stop with:
“Does this molecule work in a laboratory?”
Researchers also need to ask:
Can it survive?
Can it be absorbed?
Can it reach its target?
How much becomes available?
How quickly?
And how reproducible is that exposure?
Understanding bioavailability therefore provides another important piece of the puzzle when interpreting peptide research.
At Klarity Research, our aim is to make these commonly encountered scientific terms easier to understand so research can be interpreted in its proper context.
For educational and research information only. This article is not medical advice.